Immunotech Biopharm Ltd (HK:6978) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Immunotech Biopharm Ltd has announced that its CAR-T-19 Injection, designed for young patients with relapsed or refractory B-cell acute lymphoblastic leukemia, has received breakthrough therapy designation from China’s National Medical Products Administration. This designation is expected to fast-track the drug’s clinical development, providing early access to patients. The company’s focus on innovative cellular immunotherapy continues to drive its progress in the biopharmaceutical landscape.
For further insights into HK:6978 stock, check out TipRanks’ Stock Analysis page.